Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Chua M, Wee J, Hui E, Chan A. Nasopharyngeal carcinoma. Lancet. 2016;387:1012–1024. doi:10.1016/S0140-6736(15)00055-026321262
   PubMed Web of Science ®Google Scholar
• Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041–2054. doi:10.1016/S0140-6736(05)66698-615950718
   PubMed Web of Science ®Google Scholar
• Lo K, To K, Huang D. Focus on nasopharyngeal carcinoma. Cancer Cell. 2004;5:423–428.15144950
   PubMed Web of Science ®Google Scholar
• Tang L, Chen Q, Fan W, et al. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2013;31:2861–2869. doi:10.1200/JCO.2012.46.081623857969
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388:1883–1892. doi:10.1016/S0140-6736(16)31388-527567279
   PubMed Web of Science ®Google Scholar
• Tsang J, Lee VH, Kwong DL. Novel therapy for nasopharyngeal carcinoma–where are we. Oral Oncol. 2014;50:798–801. doi:10.1016/j.oraloncology.2014.01.00224462373
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7:2958–2970.11595683
   PubMed Web of Science ®Google Scholar
• Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005;23:3568–3576. doi:10.1200/JCO.2005.02.14715809453
   PubMed Web of Science ®Google Scholar
• You R, Sun R, Hua YJ, et al. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma. Int J Cancer. 2017;141:1265–1276. doi:10.1002/ijc.3081928577306
   PubMed Web of Science ®Google Scholar
• Lin M, You R, Liu YP, et al. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma. Oral Oncol. 2018;80:1–8. doi:10.1016/j.oraloncology.2018.03.00229706183
   PubMed Web of Science ®Google Scholar
• You R, Hua YJ, Liu YP, et al. Concurrent chemoradiotherapy with or without Anti-EGFR-targeted treatment for stage II-IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up. Theranostics. 2017;7:2314–2324. doi:10.7150/thno.1971028740554
   PubMed Web of Science ®Google Scholar
• Ji J, Yun T, Kim S, et al. A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01). Eur J Cancer. 2012;48:3198–3204. doi:10.1016/j.ejca.2012.06.00922795584
   PubMed Web of Science ®Google Scholar
• Ngan R, Yiu H, Lau W, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002;13:1252–1258. doi:10.1093/annonc/mdf20012181249
   PubMed Web of Science ®Google Scholar
• Chen C, Wang F, An X, et al. Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 2013;71:371–378. doi:10.1007/s00280-012-2020-x23143190
   PubMed Web of Science ®Google Scholar
• Chan AT, Teo PM, Leung TW, Johnson PJ. The role of chemotherapy in the management of nasopharyngeal carcinoma. Cancer. 1998;82:1003–1012. doi:10.1002/(sici)1097-0142(19980315)82:6<1003::aid-cncr1>3.0.co;2-f9506343
   PubMed Web of Science ®Google Scholar
• Zheng X, Hu L, Chen F, Christensson B. Expression of Ki67 antigen, epidermal growth factor receptor and Epstein-Barr virus-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol. 1994;30b:290–295.7703798
   PubMed Web of Science ®Google Scholar
• Roychowdhury DF, Tseng A Jr., Fu KK, et al. New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression. Cancer. 1996;77:1419–1426. doi:10.1002/(SICI)1097-0142(19960415)77:8<1419::AID-CNCR1>3.0.CO;2-78608524
   PubMed Web of Science ®Google Scholar
• Sheen TS, Huang YT, Chang YL, et al. Epstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma. Jpn J Cancer Res. 1999;90:1285–1292. doi:10.1111/j.1349-7006.1999.tb00710.x10665644
   PubMedGoogle Scholar
• Fujii M, Yamashita T, Ishiguro R, et al. Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx. 2002;29:175–181.11893453
   PubMed Web of Science ®Google Scholar
• Leong JL, Loh KS, Putti TC, et al. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope. 2004;114:153–157. doi:10.1097/00005537-200401000-0002914710013
   PubMed Web of Science ®Google Scholar
• Putti TC, To KF, Hsu HC, et al. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology. 2002;41:144–151. doi:10.1046/j.1365-2559.2002.01436.x12147092
   PubMed Web of Science ®Google Scholar
• Ma BB, Kam MK, Leung SF, et al. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2012;23:1287–1292. doi:10.1093/annonc/mdr40121948811
   PubMed Web of Science ®Google Scholar
• Liu ZG, Zhao Y, Tang J, et al. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis. Oncotarget. 2016;7:24429–24435. doi:10.18632/oncotarget.822527016412
   PubMedGoogle Scholar
• Xu T, Ou X, Shen C, Hu C. Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma. Anticancer Drugs. 2016;27:66–70. doi:10.1097/CAD.000000000000029426352217
   PubMed Web of Science ®Google Scholar
• Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. 2009;1:41–48. doi:10.4161/mabs.1.1.750920046573
   PubMed Web of Science ®Google Scholar